



**Supplementary Figure 1 Overall survival, disease-free survival, disease-free interval, and peritoneal metastases-free interval in the hyperthermic intraperitoneal chemotherapy + adjuvant chemotherapy and adjuvant chemotherapy groups before propensity score matching.** A: Overall survival; B: Disease-free survival; C: Disease-free interval; D: Peritoneal metastases-free interval.




**Supplementary Figure 2 Overall survival, disease-free survival, disease-free interval, and peritoneal metastases-free interval in the hyperthermic intraperitoneal chemotherapy + adjuvant chemotherapy and adjuvant chemotherapy groups receiving the "platinum-taxane combination regimen".**

A: Overall survival; B: Disease-free survival; C: Disease-free interval; D: Peritoneal metastases-free interval.



**Supplementary Figure 3 Overall survival, disease-free survival, disease-free interval, and peritoneal metastases-free interval in the hyperthermic intraperitoneal chemotherapy + adjuvant chemotherapy and adjuvant chemotherapy groups receiving the "SOX or XELOX regimens".** A: Overall survival; B: Disease-free survival; C: Disease-free interval; D: Peritoneal metastases-free interval.



**Supplementary Figure 4 The recurrence patterns.** A: In the HIPEC+AC group included peritoneal metastasis (n = 20; 20.83%), local recurrence (n = 11; 10.46%), and distant metastasis (n = 19; 19.79%); B: In the AC group developed peritoneal metastases (n = 43, 33.33%), local recurrence (n = 19, 14.73%), and distant metastases (n = 29, 27.13%).